Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
<p><strong>Background:</strong> The effects of the sodium-glucose co-transporter-2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD).</p> <p><strong>Methods:</...
| Main Authors: | , , |
|---|---|
| 其他作者: | |
| 格式: | Journal article |
| 語言: | English |
| 出版: |
Oxford University Press
2022
|